A Prospective, Dose Escalating, Open Label, Multi-center, Phase I/IIa Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine.
Latest Information Update: 05 Dec 2025
At a glance
- Drugs Cariprazine (Primary) ; Cariprazine (Primary)
- Indications Bipolar I disorders; Major depressive disorder; Schizophrenia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Mapi Pharma
Most Recent Events
- 29 Sep 2025 New trial record
- 17 Sep 2025 According to a Mapi Pharma media release, company has enrolled the first patient into this Phase I/II study.